(HealthDay)—For patients with glioblastoma, the addition of tumor-treating fields (TTFields) to normal remedy with temozolomide is related to improved survival with out unfavourable results on health-related high quality of life (HRQoL) aside from itchy pores and skin, in accordance to a research revealed on-line Feb. 1 in JAMA Oncology.
Martin J.B. Taphoorn, M.D., from the Haaglanden Medical Center in the Netherlands, and colleagues examined the correlation of TTFields remedy with progression-free survival and HRQoL amongst patients with glioblastoma. A complete of 695 patients with glioblastoma have been randomized after radiochemotherapy to TTFields and temozolomide or temozolomide alone in a 2-to-1 ratio. Temozolomide was given for 5 days every 28-day cycle. TTFields have been delivered constantly by way of transducer arrays positioned on the shaved scalp of patients.
The researchers discovered that there was no vital between-group distinction in HRQoL apart from extra itchy pores and skin with TTFields. Significantly longer deterioration-free survival was seen with TTFields for international well being, bodily and emotional functioning, ache, and leg weak spot, possible associated to improved progression-free survival. Reflecting the affect of remedy, time to deterioration didn’t differ considerably apart from itchy pores and skin (TTFields worse: eight.2 versus 14.four months) and ache (TTFields improved: 13.four versus 12.1 months). TTFields didn’t have an effect on position, social, or bodily functioning.
“The addition of TTFields to normal remedy with temozolomide for patients with glioblastoma outcomes in improved survival and not using a destructive affect on HRQoL apart from extra itchy pores and skin, an anticipated consequence from the transducer arrays,” the authors write.
Several authors disclosed monetary ties to pharmaceutical and medical know-how corporations, together with Novocure, which funded the research.